SCHEDULE 13G: Glazer Capital and Paul J. Glazer Disclose 5.44% Stake in Drugs Made in America Acquisition Corp.

Glazer Capital, LLC and its managing member, Paul J. Glazer, have disclosed a beneficial ownership of 5.44% in Drugs Made in America Acquisition Corp.'s Ordinary Shares.

Summary

• Glazer Capital, LLC and Paul J. Glazer, collectively referred to as the 'Reporting Persons,' have filed a Schedule 13G.
• The filing indicates beneficial ownership of 1,822,952 Ordinary Shares of DRUGS MADE IN AMERICA ACQUISITION CORP.
• This ownership represents 5.44% of the issuer's class of securities.
• Glazer Capital, LLC serves as the investment manager for certain funds and managed accounts (the 'Glazer Funds') holding these shares.
• Paul J. Glazer is the Managing Member of Glazer Capital and is also reporting beneficial ownership of the shares held by the Glazer Funds.
• The shares are held with shared voting power and shared dispositive power, with no sole voting or dispositive power reported by either entity.
• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects. It is a neutral regulatory filing.

Risks

• The filing explicitly states that the shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating a potential risk of hostile takeover or activist investor intervention.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of significant ownership by an investment firm and individual in a publicly traded company, common across all industries. It does not provide specific insights into the 'Drugs Made in America Acquisition Corp.'s' industry trends beyond its existence as a public entity.

Stakeholder Impact

• Shareholders: The disclosure of a significant 5.44% stake by Glazer Capital and Paul J. Glazer provides transparency regarding the ownership structure, which can be of interest to existing and potential shareholders. The certification that the stake is not for control purposes may reassure shareholders regarding the stability of the company's governance.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Glazer Capital, Paul J. Glazer, DRUGS MADE IN AMERICA ACQUISITION CORP., Ordinary Shares, SEC Filing, Investment Adviser, Institutional Ownership